Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
-

Ratings ESG MSCI

Ratings Concord Biotech Limited: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Highlights: Concord Biotech Limited
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Concord Biotech Limited
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 40.05 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Rating Financials

Concord Biotech Limited SectorIndia

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Concord Biotech Limited SectorIndia

Global Valuation

Enterprise value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Concord Biotech Limited SectorIndia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Concord Biotech Limited SectorIndia

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Concord Biotech Limited SectorIndia

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
156.57Cr -
7.74TCr
A
6.09TCr
BBB
5.75TCr
AA
5.59TCr
AA
2.48TCr
AA
2.08TCr
AA
1.99TCr
AAA
1.71TCr
CCC
1.59TCr -
A
- -
Average 3.52TCr
AA
Weighted average by Cap.
AA
See all sector ratings
  1. Stock Market
  2. Equities
  3. CONCORDBIO Stock
  4. Ratings Concord Biotech Limited